Clinical Trial

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 11, 2025 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-19; most recent amendment 2025-08-08.
Status change: Not Yet Recruiting → Recruiting 2025-08-08
Trial Details
NCT Number NCT05836948
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 174 participants
Start Date 2023-05-18
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-11